Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

Treatment options for highly drug-resistant tuberculosis are limited. In this study in South Africa, a new agent, pretomanid, was combined with bedaquiline and linezolid for a 26-week course to treat extensively drug-resistant and complicated multidrug-resistant pulmonary TB. Although there were tox...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 382; no. 10; pp. 893 - 902
Main Authors Conradie, Francesca, Diacon, Andreas H, Ngubane, Nosipho, Howell, Pauline, Everitt, Daniel, Crook, Angela M, Mendel, Carl M, Egizi, Erica, Moreira, Joanna, Timm, Juliano, McHugh, Timothy D, Wills, Genevieve H, Bateson, Anna, Hunt, Robert, Van Niekerk, Christo, Li, Mengchun, Olugbosi, Morounfolu, Spigelman, Melvin
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 05.03.2020
Subjects
Administration, Oral
Adolescent
Adult
Antitubercular Agents - administration & dosage
Antitubercular Agents - adverse effects
Bacterial infections
Bacterial Load
Bactericidal activity
Diarylquinolines - administration & dosage
Diarylquinolines - adverse effects
Drug dosages
Drug resistance
Drug Therapy, Combination
Enrollments
Extensively Drug-Resistant Tuberculosis - drug therapy
Extensively Drug-Resistant Tuberculosis - mortality
FDA approval
Female
Humans
Intention to Treat Analysis
Laboratories
Linezolid
Linezolid - administration & dosage
Linezolid - adverse effects
Male
Middle Aged
Multidrug resistance
Mycobacterium tuberculosis - isolation & purification
Myelosuppression
Nitroimidazoles - administration & dosage
Nitroimidazoles - adverse effects
Oral administration
Patients
Peripheral neuropathy
Protein synthesis
Safety
Treatment Outcome
Tuberculosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Pulmonary - drug therapy
Young Adult
South Africa
Online AccessGet full text

Cover

More Information
Summary:Treatment options for highly drug-resistant tuberculosis are limited. In this study in South Africa, a new agent, pretomanid, was combined with bedaquiline and linezolid for a 26-week course to treat extensively drug-resistant and complicated multidrug-resistant pulmonary TB. Although there were toxic effects, 90% of patients had favorable outcomes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1901814